非小细胞肺癌脑转移的治疗

摘要/Abstract

摘要：30%～50%的非小细胞肺癌（NSCLC）患者在疾病进展过程中发生脑转移。NSCLC脑转移是目前肿瘤治疗的难点之一，治疗措施有手术、放疗、化疗、生物靶向治疗等。目前推荐采用新的预后评分系统来预判患者的预后，根据预后评分选择个体化的治疗方法。

王小磊,刘德泽,刘微微,贾琳,王民. 非小细胞肺癌脑转移的治疗[J]. 国际肿瘤学杂志, 2015, 42(6): 455-457.

Wang Xiaolei, Liu Deze, Liu Weiwei, Jia Lin, Wang Min. Treatment of non-small cell lung cancer with brain metastasis[J]. Journal of International Oncology, 2015, 42(6): 455-457.

［1］ Kanner AA, Bokstein F, Blumenthal DT, et al. Surgical therapies in brain metas tasis［J］. Semin Oncol, 2007, 34(3): 197-205. ［2］ Ammircati M, Cobbs CS, Linskey ME, et al. The role of retreatment in the management of recurrent/progressive brain metastases: a systematic review and evidecebasedclinical practice guideline［J］. J Neurooncol, 2010, 96(1): 85-96. ［3］ Mahmood U, Kwok Y, Regine WF, et al. Wholebrain irradiation for patients with brain metastases still the standard of car［J］. Lancet Oncol, 2010, 11(3): 221-222. ［4］ Minniti G, Salvati M, Muni R, et al. Stereotacti radiosurgery plus wholebrain radiotherapy for treatment of multiople metastases from nonsmall cell lung cancer ［J］. Anticancer Res, 2010, 30(7): 3055-3061. ［5］ Yomo S, Hayashi M. The efficacy and limitations of stereotactic radiosurgery as a salvage treatment after failed whole brainradiotherapy for brain metastases［J］. J Neurooncol, 2013, 113(3): 459-465. ［6］陈秀军, 肖建平, 李祥攀, 等. 立体定向放疗与全脑放疗在多发脑转移瘤治疗中的作用分析［J］. 中华放射肿瘤学杂志, 2012, 21(1): 1-5. ［7］ Bailon O, Chouahnia K, Augier A, et al. Upfront association of carboplatin plus pemetrexed in patients with brain metastases of lung adenocarcinom［J］. Neuro Oncol, 2012, 14(4): 491-495. ［8］ Bearz A, Garassino I, Tiseo M, et al. Activity of pemetrexed on brain metastases from nonsmall cell lung cancer［J］. Lung Cancer, 2010, 68(2): 264-268. ［9］ Ortuzar W, Hanna N, Pennella E, et al. Brain metastases as the primary site of relapse in two randomized phase pemetrexed trials in advanced nonsmallcell lung cancer［J］. Clin Lung Cancer, 2012, 13(1): 24-30. ［10］ Barlesi F, Gervais R, Lena H, et al. Pemetrexed and cisplatin as firstline chemotherapy for advanced nonsmallcell lung cancer (NSCLC) with asymptomatic inoperable brain metastases: a multicenter phase Ⅱ trial (GFPC07-01)［J］. Ann Oncol, 2011, 22(11): 2466-2470. ［11］ Dinglin XX, Huang Y, Liu H, et al. Pemetrexed and cisplatin combination with concurrent whole brain radiotherapy in patientswith brain metastases of lung adenocarcinoma: a singlearmphase Ⅱ clinical trial［J］. J Neurooncol, 2013, 112(3): 461-466. ［12］ Chargari C, Pacaut C, Le Moulec S, et al. First assessment of wholebrain radiation therapy combined with pemetrexedbased chemotherapy in non-smallcell lung carcinoma: data on safety and efficacy［J］. Anticancer Drugs, 2013, 24(7): 736-742. ［13］ Bailon O, Chouahnia K, Augier A, et al. Upfront association of carboplatin plus pemetrexed in patients with brain metastases of lung adenocarcinoma［J］. Neuro Oncol, 2012, 14(4): 491-495. ［14］ Cortot AB, Geriniere L, Robinet G, et al. Phase Ⅱ trial of temozolomideand cisplatin followed by whole brain radiotherapy in non small cell lung cancer patients with brain metastases: a GlotGFPC study［J］. Ann Oncol, 2006, 17 (9): 1412-1417. ［15］ Heon S, Yeap BY, Britt GJ, et al. Development of central nervous system metastases in patients with advanced nonsmall cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib［J］. Clin Cancer Res, 2010, 16(23): 5873-5882. ［16］ Wu YL, Zhou C, Cheng Y, et al. Aphase Ⅱ study (CTONG0803) of erlotinib as secondline treatment in advanced nonsmall cell lung cancer (NSCLC) patients (pts) with asymptomatic brain metastases (BM) after firstline chemotherapy (CT)［J］. J Clin Oncol, 2011, 29(1): 7605. ［17］ Park SJ, Kim HT, Lee DH, et al. Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation［J］. Lung Cancer, 2012, 77(3): 556-560. ［18］ Welsh JW, Komaki R, Amini A, et al. Phase Ⅱ study of erlotinib with concurrent wholebrain radiation therapy for patients with brain metastases from nonsmall cell lung cancer［J］. J Clin Oncol, 2013, 31(7): 895-902. ［19］ Ettinger DS, Akerley W, Borghaei H, et al. Nonsmall cell lung cancer, version 2.2013［J］. J Natl Compr Canc Netw, 2013, 11(6): 645-653. ［20］ Andrews DW, Scott CB, Sperduto PW, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase Ⅲ results of the RTOG 9508 randomised trial［J］. Lancet, 2004, 363(4): 1665-1672.

[1]	钱晓涛, 石子宜, 胡格, 吴晓维.Ⅲ~ⅣA期食管鳞状细胞癌放化疗后行巩固化疗的疗效：一项真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(6): 326-331.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊.局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	张百红, 岳红云.新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[4]	许凤琳, 吴刚.EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[5]	王盈, 刘楠, 郭兵.抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[6]	王培鑫, 赵军, 徐世红, 姜朝阳, 王小强, 杨红娟.铁死亡相关机制在骨肉瘤中的应用进展[J]. 国际肿瘤学杂志, 2024, 51(5): 308-311.
[7]	王昆, 周中新, 臧其威.血清TGF-β1、VEGF水平对非小细胞肺癌患者单孔胸腔镜根治术后复发的预测价值[J]. 国际肿瘤学杂志, 2024, 51(4): 198-203.
[8]	萨蔷, 徐航程, 王佳玉.乳腺癌免疫治疗研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 227-234.
[9]	杨智, 陆以乔, 顾花艳, 丁佳玲, 郭贵龙.肿瘤微环境介导乳腺癌靶向治疗耐药的研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 235-238.
[10]	王子豪, 王宇, 杨鑫, 何艺, 莫兴奎, 袁涛.铁死亡在骨肉瘤中的分子机制及相关治疗的研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 239-244.
[11]	张栋岩, 王品, 魏秋亚, 邓成伍, 魏相相, 高远飞, 王琛.索凡替尼靶向联合卡培他滨和奥沙利铂治疗肝内胆管癌术后患者1例及文献复习[J]. 国际肿瘤学杂志, 2024, 51(4): 249-253.
[12]	严爱婷, 王翠竹, 刘春桂, 鲁小敏.卡瑞利珠单抗与信迪利单抗治疗晚期非小细胞肺癌的临床疗效及安全性分析[J]. 国际肿瘤学杂志, 2024, 51(3): 137-142.
[13]	李书月, 马辰莺, 周菊英, 徐晓婷, 秦颂兵.寡转移非小细胞肺癌的放疗进展[J]. 国际肿瘤学杂志, 2024, 51(3): 170-174.
[14]	彭琴, 蔡玉婷, 王伟.KPNA2在肝癌中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(3): 181-185.
[15]	岳红云, 张百红.肿瘤的分化治疗[J]. 国际肿瘤学杂志, 2024, 51(2): 109-113.

Treatment of non-small cell lung cancer with brain metastasis

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章15

编辑推荐

Metrics

本文评价